The Role of Deubiquitinating Enzymes in Cancer Drug Resistance

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2020 Mar 9

PMID 32146496

Citations 23

Authors

Parthasaradhireddy Tanguturi

Kye-Seong Kim

Suresh Ramakrishna

Affiliations

Soon will be listed here.

Abstract

Drug resistance is a well-known phenomenon leading to a reduction in the effectiveness of pharmaceutical treatments. Resistance to chemotherapeutic agents can involve various intrinsic cellular processes including drug efflux, increased resistance to apoptosis, increased DNA damage repair capabilities in response to platinum salts or other DNA-damaging drugs, drug inactivation, drug target alteration, epithelial-mesenchymal transition (EMT), inherent cell heterogeneity, epigenetic effects, or any combination of these mechanisms. Deubiquitinating enzymes (DUBs) reverse ubiquitination of target proteins, maintaining a balance between ubiquitination and deubiquitination of proteins to maintain cell homeostasis. Increasing evidence supports an association of altered DUB activity with development of several cancers. Thus, DUBs are promising candidates for targeted drug development. In this review, we outline the involvement of DUBs, particularly ubiquitin-specific proteases, and their roles in drug resistance in different types of cancer. We also review potential small molecule DUB inhibitors that can be used as drugs for cancer treatment.

Citing Articles

The other side of the coin: protein deubiquitination by Ubiquitin-Specific Protease 1 in cancer progression and therapy.

Hu X, Wu Y, Yao M, Chen Z, Li Q Future Med Chem. 2025; 17(3):329-345.

PMID: 39819213 PMC: 11792837. DOI: 10.1080/17568919.2025.2453414.

Dysregulation of deubiquitinases in gastric cancer progression.

Xu Z, Lei Z, Peng S, Fu X, Xu Y, Pan G Front Oncol. 2024; 14:1456710.

PMID: 39605891 PMC: 11598704. DOI: 10.3389/fonc.2024.1456710.

MAT1A activation of glycolysis to promote NSCLC progression depends on stabilizing CCND1.

Shen S, Liu R, Huang J, Sun Y, Tan Q, Luo Q Cell Death Dis. 2024; 15(10):768.

PMID: 39438468 PMC: 11496809. DOI: 10.1038/s41419-024-07113-7.

Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options.

Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L Mol Cancer. 2024; 23(1):88.

PMID: 38702734 PMC: 11067278. DOI: 10.1186/s12943-024-02005-y.

USP3: Key deubiquitylation enzyme in human diseases.

Zhang H, Liu W, Wu Y, Chen C Cancer Sci. 2024; 115(7):2094-2106.

PMID: 38651282 PMC: 11247611. DOI: 10.1111/cas.16178.

References

Schubert U, Anton L, Gibbs J, Norbury C, Yewdell J, Bennink J . Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 2000; 404(6779):770-4. DOI: 10.1038/35008096. View

Hershko A . The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ. 2005; 12(9):1191-7. DOI: 10.1038/sj.cdd.4401702. View

Coux O, Tanaka K, GOLDBERG A . Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996; 65:801-47. DOI: 10.1146/annurev.bi.65.070196.004101. View

Hershko A, Ciechanover A, Varshavsky A . Basic Medical Research Award. The ubiquitin system. Nat Med. 2000; 6(10):1073-81. DOI: 10.1038/80384. View

Ciechanover A, Orian A, Schwartz A . Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays. 2000; 22(5):442-51. DOI: 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q. View

Ciechanover A . Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 2005; 6(1):79-87. DOI: 10.1038/nrm1552. View

Zhang L, Xu B, Qiang Y, Huang H, Wang C, Li D . Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth. J Cell Mol Med. 2015; 19(4):799-805. PMC: 4395194. DOI: 10.1111/jcmm.12426. View

Cox J, Wilder P, Wuebben E, Ouellette M, Hollingsworth M, Rizzino A . Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2014; 15(8):1042-52. PMC: 4119071. DOI: 10.4161/cbt.29182. View

Komander D, Clague M, Urbe S . Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009; 10(8):550-63. DOI: 10.1038/nrm2731. View

10.

Pfoh R, Lacdao I, Saridakis V . Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocr Relat Cancer. 2015; 22(1):T35-54. PMC: 4304536. DOI: 10.1530/ERC-14-0516. View

11.

Wilkinson K . DUBs at a glance. J Cell Sci. 2009; 122(Pt 14):2325-9. PMC: 2704873. DOI: 10.1242/jcs.041046. View

12.

Ramakrishna S, Suresh B, Baek K . The role of deubiquitinating enzymes in apoptosis. Cell Mol Life Sci. 2010; 68(1):15-26. PMC: 11115095. DOI: 10.1007/s00018-010-0504-6. View

13.

Farshi P, Deshmukh R, Nwankwo J, Arkwright R, Cvek B, Liu J . Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opin Ther Pat. 2015; 25(10):1191-1208. PMC: 4834700. DOI: 10.1517/13543776.2015.1056737. View

14.

Darcy P, Wang X, Linder S . Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther. 2014; 147:32-54. DOI: 10.1016/j.pharmthera.2014.11.002. View

15.

Adams J . The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004; 4(5):349-60. DOI: 10.1038/nrc1361. View

16.

Song M, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J . The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature. 2008; 455(7214):813-7. PMC: 3398484. DOI: 10.1038/nature07290. View

17.

Nijman S, Luna-Vargas M, Velds A, Brummelkamp T, Dirac A, Sixma T . A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005; 123(5):773-86. DOI: 10.1016/j.cell.2005.11.007. View

18.

Zhou M, Chen F, Chen H . Ubiquitination involved enzymes and cancer. Med Oncol. 2014; 31(8):93. DOI: 10.1007/s12032-014-0093-6. View

19.

Voutsadakis I . Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer. Tumour Biol. 2012; 33(4):897-910. DOI: 10.1007/s13277-012-0355-x. View

20.

Lander G, Estrin E, Matyskiela M, Bashore C, Nogales E, Martin A . Complete subunit architecture of the proteasome regulatory particle. Nature. 2012; 482(7384):186-91. PMC: 3285539. DOI: 10.1038/nature10774. View